CAMBRIDGE, Mass.—The U.S. Food and Drug Administration (FDA) has approved a 2 mcg/mL vial dosing option of Hectorol (doxercalciferol injection), for the treatment of secondary hyperparathyroidism in patients with CKD on dialysis, according to a Dec. 22 news release.
“We understand that dosing flexibility is very important to the nephrology community and we are pleased to add this new dosing option to our portfolio,” said Rogerio Vivaldi, president of Genzyme’s Renal and Endocrinology business unit. “The introduction of a single use, 2 mcg/mL vial dosing option for Hectorol will help enable health care providers to utilize fewer resources to achieve effective PTH reduction.”
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection).
